Cargando…

Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone

Renal fibrosis is the inevitable pathway of the progression of chronic kidney disease to end-stage renal disease, which manifests as progressive glomerulosclerosis and renal interstitial fibrosis. In a previous study, we observed severe interstitial fibrosis in the contralateral kidneys of 6-month u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qiang, Panpan, Hao, Juan, Yang, Fan, Han, Yutong, Chang, Yi, Xian, Yunqian, Xiong, Yunzhao, Gao, Xiaomeng, Liang, Lijuan, Shimosawa, Tatsuo, Xu, Qingyou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485811/ https://www.ncbi.nlm.nih.gov/pubmed/36148244 http://dx.doi.org/10.3389/fimmu.2022.948658

Ejemplares similares

Esaxerenone Inhibits Renal Angiogenesis and Endothelial-Mesenchymal Transition via the VEGFA and TGF-β1 Pathways in Aldosterone-Infused Mice
por: Gao, Xiaomeng, et al.
Publicado: (2023)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

SUN-176 A Case of Aldosterone-Producing Adenoma with Preoperative Use of a Novel Mineralocorticoid Receptor Antagonist Esaxerenone
por: Yamanami, Hiroaki
Publicado: (2020)

Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism
por: Satoh, Fumitoshi, et al.
Publicado: (2020)

Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism
por: Fujimoto, Masanori, et al.
Publicado: (2023)

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone
por: Rakugi, Hiromi, et al.
Publicado: (2020)

Eplerenone Attenuates Fibrosis in the Contralateral Kidney of UUO Rats by Preventing Macrophage-to-Myofibroblast Transition
por: Xiong, Yunzhao, et al.
Publicado: (2021)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats
por: Rahman, Asadur, et al.
Publicado: (2021)

Characterization of Direct Perturbations on Voltage-Gated Sodium Current by Esaxerenone, a Nonsteroidal Mineralocorticoid Receptor Blocker
por: Chang, Wei-Ting, et al.
Publicado: (2021)

A Case of a Pregnant Woman With Primary Aldosteronism and Superimposed Preeclampsia Treated With Esaxerenone
por: Yamashita, Kaoru, et al.
Publicado: (2022)

Effects of itraconazole and rifampicin on the single‐dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects
por: Kirigaya, Yoshiaki, et al.
Publicado: (2020)

Eplerenone Prevents Cardiac Fibrosis by Inhibiting Angiogenesis in Unilateral Urinary Obstruction Rats
por: Chang, Yi, et al.
Publicado: (2022)

Aldosterone and Mineralocorticoid Receptors—Physiology and Pathophysiology
por: Funder, John W.
Publicado: (2017)

Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study
por: Kario, Kazuomi, et al.
Publicado: (2020)

A Selective Mineralocorticoid Receptor Blocker, Esaxerenone, Attenuates Vascular Dysfunction in Diabetic C57BL/6 Mice
por: Munkhjargal, Uugantsetseg, et al.
Publicado: (2023)

Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE‐HT study
por: Kario, Kazuomi, et al.
Publicado: (2023)

Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke
por: Dinh, Quynh N, et al.
Publicado: (2012)

Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone
por: Muñoz-Durango, N., et al.
Publicado: (2015)

Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging
por: Gorini, Stefania, et al.
Publicado: (2019)

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
por: Bamberg, Krister, et al.
Publicado: (2019)

A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity
por: Okamura, Keisuke, et al.
Publicado: (2020)

Aldosterone and Mineralocorticoid Receptor System in Cardiovascular Physiology and Pathophysiology
por: Cannavo, Alessandro, et al.
Publicado: (2018)

Aldosterone Induces the Proliferation of Renal Tubular Epithelial Cells In Vivo but Not In Vitro
por: Hao, Juan, et al.
Publicado: (2021)

Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats
por: Martín-Fernández, Beatriz, et al.
Publicado: (2016)

The Kidneys and Aldosterone/Mineralocorticoid Receptor System in Salt-Sensitive Hypertension
por: Shibata, Shigeru, et al.
Publicado: (2011)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2021)

Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists
por: Yoshida, Yuichi, et al.
Publicado: (2021)

Macrophage-Myofibroblast Transition Contributes to Myofibroblast Formation in Proliferative Vitreoretinal Disorders
por: Abu El-Asrar, Ahmed M., et al.
Publicado: (2023)

Interaction of the Mineralocorticoid Receptor With RACK1 and Its Role in Aldosterone Signaling
por: Kuppusamy, Maniselvan, et al.
Publicado: (2017)

SAT-564 Effectiveness of Treatment with Mineralocorticoid Receptor Antagonistsin Primary Aldosteronism
por: Tezuka, Yuta, et al.
Publicado: (2020)

SAT-561 Effects of Mineralocorticoid Receptor Antagonists on Primary Aldosteronism Screening
por: Tezuka, Yuta, et al.
Publicado: (2020)

The Glucocorticoid Receptor is Required for Efficient Aldosterone-Induced Transcription by the Mineralocorticoid Receptor.
por: Johnson, Thomas A., et al.
Publicado: (2023)

Eplerenone ameliorates lung fibrosis in unilateral ureteral obstruction rats by inhibiting lymphangiogenesis
por: Liu, Ziqian, et al.
Publicado: (2022)

The role of the macrophage-to-myofibroblast transition in renal fibrosis
por: Wei, Jia, et al.
Publicado: (2022)

Cardiac Hypertrophy and Fibrosis in the Metabolic Syndrome: A Role for Aldosterone and the Mineralocorticoid Receptor
por: Essick, Eric E., et al.
Publicado: (2011)

The Diuretic Torasemide Does Not Prevent Aldosterone-Mediated Mineralocorticoid Receptor Activation in Cardiomyocytes
por: Gravez, Basile, et al.
Publicado: (2013)

Mineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease
por: Gorini, Stefania, et al.
Publicado: (2018)

PSUN68 Finerenone for Primary Aldosteronism: A Novel Mineralocorticoid Receptor Antagonist
por: Aurora, John, et al.
Publicado: (2022)

Spontaneous Remission of Primary Aldosteronism with Mineralocorticoid Receptor Antagonist Therapy: A Review
por: Mai, Xurong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j88r9imvpga99g0ht47naqg19u